AAVXF:OTCMKTS
Abivax SA
USD 139,00
0,00%
(0,00) 1D
9 Jul., 09:30:01 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AAVXF...
Mkt. cap
6,81 mjd
Avg. vol.
0,00
Volume
0,00
52-wk high
USD 139,00
52-wk low
USD 71,26
Beta
3,09
Shares outstanding
87,53 m
No. of employees
98
Mkt. cap
6,81 mjd
Avg. vol.
0,00
Volume
0,00
52-wk high
USD 139,00
52-wk low
USD 71,26
Beta
3,09
Shares outstanding
87,53 m
No. of employees
98
News stories
From web sources and news partners
TradingView
·
1 dag gelede
Abivax SA Stock 12‑Month Price Target Cut to $159.06, Implies 79% Upside
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
About Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Employees98
Founded04 Des. 2013
Headquarters-
Sector-
Websiteabivax.com